Robert John Lyng

Title: Innovations by Robert John Lyng in Treating Mucopolysaccharidosis IIIB

Introduction

Robert John Lyng is an accomplished inventor based in Lexington, MA (US). He has made significant contributions to the field of medicine, particularly in the treatment of rare diseases. His innovative approach focuses on methods for treating Mucopolysaccharidosis IIIB (MPSIIIB), a condition that affects the central nervous system.

Latest Patents

Robert John Lyng holds a patent for "Methods of treating Mucopolysaccharidosis IIIB (MPSIIIB)." This patent outlines methods for treating the central nervous system in human patients with MPS who have an intact blood-brain barrier. The treatment involves the intravenous administration of recombinant NaGlu, showcasing his commitment to advancing medical therapies.

Career Highlights

Lyng is currently associated with Alexion Pharmaceuticals, Inc., a leading biopharmaceutical company known for its focus on rare diseases. His work at Alexion has allowed him to collaborate with other experts in the field and contribute to groundbreaking research.

Collaborations

Some of his notable coworkers include Anthony Quinn and Sandra Rojas-Caro. Their collective expertise enhances the innovative environment at Alexion Pharmaceuticals, fostering advancements in treatment methodologies.

Conclusion

Robert John Lyng's contributions to the treatment of Mucopolysaccharidosis IIIB highlight his role as a key innovator in the medical field. His patent and work at Alexion Pharmaceuticals demonstrate his dedication to improving patient outcomes through innovative therapies.